ECSP045136A - Polimorfo de clorhidrato de venlafaxina novedoso y metodos para la preparacion del mismo - Google Patents

Polimorfo de clorhidrato de venlafaxina novedoso y metodos para la preparacion del mismo

Info

Publication number
ECSP045136A
ECSP045136A EC2004005136A ECSP045136A ECSP045136A EC SP045136 A ECSP045136 A EC SP045136A EC 2004005136 A EC2004005136 A EC 2004005136A EC SP045136 A ECSP045136 A EC SP045136A EC SP045136 A ECSP045136 A EC SP045136A
Authority
EC
Ecuador
Prior art keywords
methods
chlorhydrate
venlafaxine
polymorph
preparation
Prior art date
Application number
EC2004005136A
Other languages
English (en)
Inventor
Jun Han
Kadum Abdul Nabi Ali
Yong Jai Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP045136A publication Critical patent/ECSP045136A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención corresponde a una forma polimórfica de clorhidrato de venlafaxina cristalino anhídrido novedoso estable altamente térmico, métodos para la preparación del mismo y sus utilidades
EC2004005136A 2001-12-05 2004-06-04 Polimorfo de clorhidrato de venlafaxina novedoso y metodos para la preparacion del mismo ECSP045136A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33582201P 2001-12-05 2001-12-05

Publications (1)

Publication Number Publication Date
ECSP045136A true ECSP045136A (es) 2004-07-23

Family

ID=23313356

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005136A ECSP045136A (es) 2001-12-05 2004-06-04 Polimorfo de clorhidrato de venlafaxina novedoso y metodos para la preparacion del mismo

Country Status (21)

Country Link
US (2) US7030164B2 (es)
EP (1) EP1451145A1 (es)
JP (1) JP2005511736A (es)
KR (1) KR20050044673A (es)
CN (1) CN1630631A (es)
AR (1) AR037744A1 (es)
AU (1) AU2002348266A1 (es)
BR (1) BR0214742A (es)
CA (1) CA2467593A1 (es)
CO (1) CO5580818A2 (es)
EC (1) ECSP045136A (es)
HU (1) HUP0402524A2 (es)
IL (1) IL162255A0 (es)
MX (1) MXPA04005305A (es)
NO (1) NO20042681L (es)
NZ (1) NZ533363A (es)
PL (1) PL370552A1 (es)
RU (1) RU2004120285A (es)
TW (1) TW200301101A (es)
WO (1) WO2003050075A1 (es)
ZA (1) ZA200405248B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
CA2574315A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
US20060020015A1 (en) * 2004-07-22 2006-01-26 Wyeth Method for treating nervous system disorders and conditions
AU2005266997A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
KR20080056311A (ko) * 2005-10-19 2008-06-20 테바 파마슈티컬 인더스트리즈 리미티드 고순도1-[2-디메틸아미노-(4-메톡시페닐)에틸)시클로헥산올염산염의 제조 방법
NZ599480A (en) * 2007-02-21 2013-10-25 Sunovion Pharmaceuticals Inc Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
KR101477154B1 (ko) 2010-10-01 2014-12-29 산동 루예 파마슈티칼 컴파니 리미티드 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DE69429895T2 (de) 1993-06-28 2002-08-29 American Home Products Corp., Madison Neue Behandlungsmethoden durch Verwendung von Phenethylderivaten
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US5530013A (en) 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
US5506270A (en) 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
KR20030059206A (ko) 2000-10-19 2003-07-07 테바 파마슈티컬 인더스트리즈 리미티드 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
WO2002046140A1 (en) 2000-12-07 2002-06-13 Dr. Reddy's Laboratories Ltd. Novel crystalline polymorphic forms of venlafaxine hydrochloride and a process for their preparation
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)

Also Published As

Publication number Publication date
US20030109585A1 (en) 2003-06-12
KR20050044673A (ko) 2005-05-12
RU2004120285A (ru) 2005-04-10
US7030164B2 (en) 2006-04-18
TW200301101A (en) 2003-07-01
WO2003050075A1 (en) 2003-06-19
IL162255A0 (en) 2005-11-20
AU2002348266A1 (en) 2003-06-23
NZ533363A (en) 2005-10-28
CA2467593A1 (en) 2003-06-19
JP2005511736A (ja) 2005-04-28
PL370552A1 (en) 2005-05-30
HUP0402524A2 (hu) 2005-03-29
US20060074131A1 (en) 2006-04-06
CN1630631A (zh) 2005-06-22
CO5580818A2 (es) 2005-11-30
MXPA04005305A (es) 2004-09-13
NO20042681L (no) 2004-06-25
ZA200405248B (en) 2005-10-03
BR0214742A (pt) 2004-09-14
EP1451145A1 (en) 2004-09-01
AR037744A1 (es) 2004-12-01

Similar Documents

Publication Publication Date Title
ECSP045088A (es) Forma polimorfica de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
CL2007002949A1 (es) Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora;
UY31344A1 (es) Metansulfonamidas n-(3-ter-butil-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-2-metoxi-aril) sustituidas, solvatos, hidratos, formas cristalinas y sus sales farmacéuticamente aceptables,proceso de preparación,composiciones y aplicaciones.
TW200716512A (en) Processes for preparing cinacalcet hydrochloride crystal form I
ECSP088098A (es) Nuevos regímenes para anticonceptivos orales monofásicos
IL183237A0 (en) Polymorphs of memantine hydrochloride
EP2123250A4 (en) COMPOSITION FOR CONTROL OF HAIR FORM
ECSP045136A (es) Polimorfo de clorhidrato de venlafaxina novedoso y metodos para la preparacion del mismo
DK1651622T3 (da) Fremgangsmåde til fremstilling af 2-(quinoxalin-5-ylsulfonylamino)-benzamidforbindelser
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
TW200420541A (en) Crystalline forms
AR051754A1 (es) Metodos para preparar compuestos de indazol
EP2001856A4 (en) CRYSTALLINE FORMS OF N- {2-TERT-BUTYL-1 - [(4,4-DIFLUOROCYCLOHEXYL) METHYL] -1H-BENZIMIDAZOL-5-YL} ETHANESULFONAMIDE SALTS
MXPA04005307A (es) Clorhidrato de venlafaxina en forma de monohidrato y sus metodos de preparacion.
ITMO20030031A1 (it) Procedimento estrusivo per la formatura di manufatti
EA200901088A1 (ru) Способ получения 5-бензилокси-2-(4-бензилоксифенил)-3-метил-1н-индола
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
ITMI20030018A1 (it) Procedimento per la preparazione di composti mono-
EA200970116A1 (ru) Кристаллический гидрохлорид неморубицина
ITMI20030019A1 (it) Procedimento per la preparazione di composti mono-
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
ITMI20030176A1 (it) Procedimento per la preparazione di gabapentina "forma ii" pura
MX2009003449A (es) Vacuna terapeutica que comprende la proteina de choque termico micobacteriana 70.
WO2004069790A3 (en) Crystalline modifications of triazinylaminostilbenes
BRPI0605859A (pt) processos para preparar a forma i cristalina de cloridrato de cinacalcet